Sodium-glucose cotransporter 2 (SGLT2) inhibitors have been developed as a new therapeutic agent for the treatment of type 2 diabetes mellitus (T2DM), which can inhibit the proximal renal tubular SGLT protein family reabsorption of glucose, thereby reducing blood sugar levels (Chao and Henry, 2010). This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.